Concepts (56)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oncolytic Virotherapy | 9 | 2024 | 90 | 3.020 |
Why?
|
| Oncolytic Viruses | 7 | 2024 | 77 | 2.160 |
Why?
|
| Adenoviridae | 7 | 2024 | 610 | 1.920 |
Why?
|
| Neoplasms | 8 | 2025 | 3029 | 1.030 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2021 | 887 | 0.980 |
Why?
|
| Cell Plasticity | 1 | 2025 | 36 | 0.920 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2025 | 119 | 0.900 |
Why?
|
| Myeloid Cells | 1 | 2025 | 123 | 0.890 |
Why?
|
| Alternative Splicing | 1 | 2025 | 375 | 0.790 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2021 | 165 | 0.620 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 1810 | 0.600 |
Why?
|
| Adoptive Transfer | 1 | 2018 | 241 | 0.550 |
Why?
|
| Inflammation | 1 | 2025 | 1591 | 0.540 |
Why?
|
| Genetic Therapy | 2 | 2020 | 733 | 0.480 |
Why?
|
| Interleukin-12 | 3 | 2021 | 122 | 0.460 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 1309 | 0.460 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 732 | 0.460 |
Why?
|
| B7-H1 Antigen | 3 | 2021 | 129 | 0.420 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 701 | 0.370 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 873 | 0.360 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2024 | 1006 | 0.360 |
Why?
|
| Tumor Burden | 2 | 2021 | 257 | 0.300 |
Why?
|
| Receptor, ErbB-2 | 3 | 2021 | 559 | 0.270 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2020 | 500 | 0.240 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 802 | 0.220 |
Why?
|
| Immunity, Innate | 1 | 2025 | 416 | 0.190 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 3754 | 0.190 |
Why?
|
| Single-Chain Antibodies | 1 | 2021 | 45 | 0.170 |
Why?
|
| Coculture Techniques | 1 | 2021 | 246 | 0.170 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 690 | 0.160 |
Why?
|
| Animals | 7 | 2025 | 36424 | 0.160 |
Why?
|
| Antibodies, Bispecific | 1 | 2020 | 51 | 0.160 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 746 | 0.140 |
Why?
|
| Antibodies, Neoplasm | 1 | 2017 | 60 | 0.140 |
Why?
|
| Lymphocyte Transfusion | 1 | 2017 | 58 | 0.140 |
Why?
|
| Viral Tropism | 1 | 2016 | 53 | 0.120 |
Why?
|
| Transduction, Genetic | 1 | 2016 | 296 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2017 | 1596 | 0.110 |
Why?
|
| Antibodies, Neutralizing | 1 | 2017 | 496 | 0.110 |
Why?
|
| Gene Expression | 1 | 2017 | 1616 | 0.100 |
Why?
|
| Humans | 8 | 2025 | 133717 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 1068 | 0.090 |
Why?
|
| Mice | 4 | 2024 | 18949 | 0.080 |
Why?
|
| Female | 5 | 2024 | 71608 | 0.070 |
Why?
|
| Clinical Studies as Topic | 1 | 2020 | 10 | 0.040 |
Why?
|
| Hyaluronan Receptors | 1 | 2020 | 68 | 0.040 |
Why?
|
| Male | 3 | 2021 | 65858 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 318 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2024 | 745 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2020 | 613 | 0.040 |
Why?
|
| A549 Cells | 1 | 2017 | 49 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 97 | 0.030 |
Why?
|
| Cytokines | 1 | 2023 | 1396 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2020 | 970 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2017 | 777 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2020 | 13003 | 0.030 |
Why?
|